Zurich-Schlieren, Switzerland, 7 September 2023
We are thrilled to announce that TOPADUR Pharma AG has once again been recognized as one of Switzerland's top 25 scale-up companies.
This achievement is a demonstration to our team's dedication and our partners' support.
We are grateful for this recognition and remain committed to pushing the boundaries of innovation in the years to come.
Please check out the link below.
TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.
Read moreTOPADUR Pharma AG announces dosing of first healthy subjects in Phase 1 clinical trial of TOP-N53.
Read moreWe are proud to be recognized as one of Switzerland's most promising scale-ups in 2023.
Read more